Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

A study will assess changes in employment status and sick days when people take the drug. Weight loss drugs could be given to unemployed people with obesity as a way of getting them into work, British ...

Wylie said: "Ozempic (semaglutide) is a medication licensed for the management of type 2 diabetes. While it has shown ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

(Reuters) - Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

The future of the weight loss market might not revolve around GLP-1 drugs.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk CEO Lars Fruergaard Jorgensen has called attention to the complexities of the U.S. healthcare system while ...

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

Researchers at Massachusetts General Hospital have discovered that meeting the weekly recommended physical activity levels, ...